AU2003270439B2
(en)
|
2002-09-11 |
2009-09-24 |
Genentech, Inc. |
Novel composition and methods for the treatment of immune related diseases
|
PL2279412T3
(pl)
|
2008-04-09 |
2017-12-29 |
Genentech, Inc. |
Nowe kompozycje i sposoby leczenia chorób o podłożu immunologicznym
|
US9017660B2
(en)
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
DK2853269T3
(da)
|
2008-05-19 |
2019-08-05 |
Advaxis Inc |
Dobbelt indgivelsessystem til heterologe antigener, der omfatter en rekombinant Listeria-stamme svækket ved mutation af dal/dat og deletion af ActA, der omfatter et nukleinsyremolekyle, der koder for et listeriolysin O-prostataspecifikt antigenfusionsprotein
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
PE20120341A1
(es)
|
2008-12-09 |
2012-04-24 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
|
US10016617B2
(en)
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
WO2012138377A2
(en)
|
2010-10-01 |
2012-10-11 |
Trustees Of The University Of Pennsylvania |
The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
|
CN103687611A
(zh)
|
2011-03-11 |
2014-03-26 |
阿德瓦希斯公司 |
基于李斯特菌属的佐剂
|
AU2012236367B2
(en)
|
2011-04-01 |
2014-10-09 |
Curis, Inc. |
Phosphoinositide 3-kinase inhibitor with a zinc binding moiety
|
WO2012166899A2
(en)
|
2011-06-03 |
2012-12-06 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
ES2708669T3
(es)
|
2011-08-01 |
2019-04-10 |
Hoffmann La Roche |
Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 e inhibidores de MEK
|
EP2806883B1
(en)
|
2012-01-25 |
2019-04-24 |
DNAtrix, Inc. |
Biomarkers and combination therapies using oncolytic virus and immunomodulation
|
WO2013138337A1
(en)
|
2012-03-12 |
2013-09-19 |
Advaxis |
Suppressor cell function inhibition following listeria vaccine treatment
|
CN103566377A
(zh)
|
2012-07-18 |
2014-02-12 |
上海博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
US20150231241A1
(en)
|
2012-08-14 |
2015-08-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
MX2015010854A
(es)
*
|
2013-03-14 |
2016-07-20 |
Genentech Inc |
Combinaciones de un compuesto inhibidor de mek con un compuesto inhibidor de her3/egfr y metodos de uso.
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
RU2701378C2
(ru)
*
|
2013-03-15 |
2019-09-26 |
Дженентек, Инк. |
Биомаркеры и способы лечения связанных с pd-1 и pd-l1 состояний
|
CA2899577C
(en)
*
|
2013-04-03 |
2023-10-17 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
EP3003316B1
(en)
*
|
2013-05-31 |
2020-07-22 |
Merck Sharp & Dohme Corp. |
Combination therapies for cancer
|
WO2014195852A1
(en)
*
|
2013-06-03 |
2014-12-11 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
|
WO2014204856A1
(en)
*
|
2013-06-17 |
2014-12-24 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid anticancer derivatives and their uses
|
SG11201600310QA
(en)
*
|
2013-07-16 |
2016-02-26 |
Genentech Inc |
Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
|
AR097279A1
(es)
|
2013-08-09 |
2016-03-02 |
Actelion Pharmaceuticals Ltd |
Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
RU2705795C2
(ru)
*
|
2013-08-20 |
2019-11-12 |
Мерк Шарп И Доум Корп. |
Лечение рака комбинацией антагониста pd-1 и динациклиба
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
CN108715615B
(zh)
*
|
2013-09-13 |
2020-11-27 |
百济神州(广州)生物科技有限公司 |
抗pd1抗体及其作为治疗剂与诊断剂的用途
|
EP3049442A4
(en)
*
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
SG10201708542RA
(en)
*
|
2013-09-27 |
2017-12-28 |
Genentech Inc |
Anti-pdl1 antibody formulations
|
ES2714708T3
(es)
|
2013-10-01 |
2019-05-29 |
Mayo Found Medical Education & Res |
Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
|
WO2015088930A1
(en)
*
|
2013-12-10 |
2015-06-18 |
Merck Sharp & Dohme Corp. |
Immunohistochemical proximity assay for pd-1 positive cells and pd-ligand positive cells in tumor tissue
|
MY184154A
(en)
|
2013-12-12 |
2021-03-23 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
EP3084003A4
(en)
|
2013-12-17 |
2017-07-19 |
Merck Sharp & Dohme Corp. |
Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists
|
SG11201604995YA
(en)
*
|
2013-12-17 |
2016-07-28 |
Genentech Inc |
Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
|
US20150190506A1
(en)
*
|
2013-12-17 |
2015-07-09 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
SG11201604875PA
(en)
*
|
2013-12-17 |
2016-07-28 |
Genentech Inc |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
JP2017502068A
(ja)
|
2014-01-10 |
2017-01-19 |
シャンハイ バーディー バイオテック インコーポレイテッド |
Her2陽性腫瘍を処置するための化合物及び組成物
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
CN106456753B
(zh)
|
2014-02-04 |
2021-05-11 |
因塞特公司 |
用于治疗癌症的pd-1拮抗剂和ido1抑制剂的组合
|
PT3102605T
(pt)
|
2014-02-04 |
2019-02-12 |
Pfizer |
Combinação de um antagonista da mp-1 e um inibidor do rfcev para o tratamento do cancro
|
TW201613635A
(en)
|
2014-02-04 |
2016-04-16 |
Pfizer |
Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
|
JP6731346B2
(ja)
*
|
2014-02-10 |
2020-07-29 |
メルク パテント ゲーエムベーハー |
標的TGFβ阻害
|
KR20220126813A
(ko)
|
2014-03-14 |
2022-09-16 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
JP6894236B2
(ja)
*
|
2014-03-26 |
2021-06-30 |
デノボ バイオファーマ エルエルシー |
免疫刺激活性を有するレトロウイルスベクター
|
MA39817A
(fr)
|
2014-03-31 |
2017-02-08 |
Hoffmann La Roche |
Thérapie combinatoires comprenant des agents anti-angiogenèse et des agonistes se liant à ox40
|
US10302653B2
(en)
|
2014-05-22 |
2019-05-28 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti B7-H1 antibodies
|
JP2017516779A
(ja)
|
2014-05-28 |
2017-06-22 |
アイデニクス・ファーマシューティカルズ・エルエルシー |
癌治療のためのヌクレオシド誘導体
|
KR102204937B1
(ko)
|
2014-06-06 |
2021-01-18 |
브리스톨-마이어스 스큅 컴퍼니 |
글루코코르티코이드-유도 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
|
CN110156892B
(zh)
|
2014-07-03 |
2023-05-16 |
百济神州有限公司 |
抗pd-l1抗体及其作为治疗剂及诊断剂的用途
|
JP6760919B2
(ja)
|
2014-07-09 |
2020-09-23 |
バーディー バイオファーマシューティカルズ インコーポレイテッド |
腫瘍を治療するための抗pd−l1組み合わせ
|
JP7032929B2
(ja)
|
2014-07-11 |
2022-03-09 |
ヴェンタナ メディカル システムズ, インク. |
抗pd-l1抗体及びその診断上の使用
|
EP3169361B1
(en)
*
|
2014-07-15 |
2019-06-19 |
F.Hoffmann-La Roche Ag |
Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
CN106999561A
(zh)
|
2014-07-18 |
2017-08-01 |
阿德瓦希斯股份有限公司 |
用于治疗***癌的pd‑1拮抗剂和基于李斯特菌的疫苗的组合
|
NZ728688A
(en)
|
2014-07-22 |
2023-06-30 |
Cb Therapeutics Inc |
Anti-pd-1 antibodies
|
EP3171896A4
(en)
|
2014-07-23 |
2018-03-21 |
Mayo Foundation for Medical Education and Research |
Targeting dna-pkcs and b7-h1 to treat cancer
|
JP6909153B2
(ja)
|
2014-08-05 |
2021-07-28 |
アポロミクス インコーポレイテッド |
抗pd−l1抗体
|
PL3177644T3
(pl)
|
2014-08-05 |
2021-06-14 |
MabQuest SA |
Immunologiczne reagenty wiążące do PD-1
|
US9982052B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
DK3177640T3
(da)
|
2014-08-08 |
2020-08-10 |
Univ Leland Stanford Junior |
Pd-1-midler med høj affinitet og anvendelsesfremgangsmåder
|
DK3180087T3
(da)
|
2014-08-12 |
2019-05-13 |
Alligator Bioscience Ab |
Kombinationsterapier med anti cd40-antistoffer
|
RU2017108173A
(ru)
*
|
2014-08-14 |
2018-09-17 |
Ф.Хоффманн-Ля Рош Аг |
Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1
|
EP3070102A1
(en)
*
|
2015-03-18 |
2016-09-21 |
F. Hoffmann-La Roche AG |
Combination therapy of antibodies human cd40 activating antibodies and anti human pld-1 antibodies
|
WO2016032927A1
(en)
|
2014-08-25 |
2016-03-03 |
Pfizer Inc. |
Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
|
KR102512940B1
(ko)
|
2014-08-28 |
2023-03-23 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
고순도의 퀴놀린 유도체 및 이를 제조하는 방법
|
ES2727137T3
(es)
|
2014-08-28 |
2019-10-14 |
Halozyme Inc |
Terapia combinada con una enzima de degradación de hialuronano y un inhibidor de puntos de control inmunitario
|
CN112587672A
(zh)
*
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于***的抗-pd-l1结合物
|
US9535074B2
(en)
|
2014-09-08 |
2017-01-03 |
Merck Sharp & Dohme Corp. |
Immunoassay for soluble PD-L1
|
WO2016040880A1
(en)
*
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies of alk inhibitors
|
JP2017534577A
(ja)
*
|
2014-09-15 |
2017-11-24 |
ジェネンテック, インコーポレイテッド |
Pd−1軸結合拮抗薬及びil−17結合拮抗薬を使用したがんの治療方法
|
AU2015316991B2
(en)
|
2014-09-16 |
2021-04-01 |
Innate Pharma |
Neutralization of inhibitory pathways in lymphocytes
|
KR20170066546A
(ko)
|
2014-10-03 |
2017-06-14 |
노파르티스 아게 |
조합 요법
|
JP7037359B2
(ja)
|
2014-10-10 |
2022-03-16 |
イナート・ファルマ・ソシエテ・アノニム |
Cd73遮断
|
KR20170072244A
(ko)
|
2014-10-10 |
2017-06-26 |
이데라 파마슈티칼즈, 인코포레이티드 |
관문 억제제를 가지는 tlr9 효능제를 이용한 암 치료
|
AU2015333687B2
(en)
|
2014-10-14 |
2021-03-18 |
Dana-Farber Cancer Institute, Inc. |
Antibody molecules to PD-L1 and uses thereof
|
CN108064282A
(zh)
|
2014-10-14 |
2018-05-22 |
哈洛齐梅公司 |
腺苷脱氨酶-2(ada2)、其变体的组合物及使用其的方法
|
KR20170096112A
(ko)
*
|
2014-11-17 |
2017-08-23 |
제넨테크, 인크. |
Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
|
HRP20221083T1
(hr)
*
|
2014-11-20 |
2022-11-25 |
F. Hoffmann - La Roche Ag |
Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t stanice i antagonistom vezivanja osi pd-1
|
CN105669862A
(zh)
*
|
2014-11-21 |
2016-06-15 |
上海中信国健药业股份有限公司 |
抗人pd-l1/kir双特异性抗体及其制备方法和应用
|
KR20170101925A
(ko)
*
|
2014-12-02 |
2017-09-06 |
셀진 코포레이션 |
병용 요법
|
EP3226690B1
(en)
|
2014-12-05 |
2020-05-20 |
Merck Sharp & Dohme Corp. |
Novel tricyclic compounds as inhibitors of mutant idh enzymes
|
JP2017537929A
(ja)
*
|
2014-12-05 |
2017-12-21 |
ジェネンテック, インコーポレイテッド |
Pd−1軸アンタゴニスト及びhpk1アンタゴニストを用いたがん治療のための方法及び組成物
|
EP3226688B1
(en)
|
2014-12-05 |
2020-07-01 |
Merck Sharp & Dohme Corp. |
Tricyclic compounds as inhibitors of mutant idh enzymes
|
WO2016089830A1
(en)
|
2014-12-05 |
2016-06-09 |
Merck Sharp & Dohme Corp. |
Novel tricyclic compounds as inhibitors of mutant idh enzymes
|
CA2968406A1
(en)
|
2014-12-09 |
2016-06-16 |
Mark D. Ayers |
System and methods for deriving gene signature biomarkers of response to pd-1 antagonists
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
US20170363614A1
(en)
*
|
2014-12-22 |
2017-12-21 |
Enumeral Biomedical Holdings, Inc. |
Methods For Screening Therapeutic Compounds
|
CN107208138A
(zh)
*
|
2014-12-30 |
2017-09-26 |
豪夫迈·罗氏有限公司 |
用于癌症预后和治疗的方法和组合物
|
JP2016155776A
(ja)
*
|
2015-02-24 |
2016-09-01 |
学校法人兵庫医科大学 |
抗腫瘍効果増強剤および抗腫瘍剤
|
JP6792546B2
(ja)
|
2015-02-25 |
2020-11-25 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
キノリン誘導体の苦味抑制方法
|
JP6885869B2
(ja)
|
2015-02-26 |
2021-06-16 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
がんを治療するためのpd−1/pd−l1阻害剤
|
RU2737216C2
(ru)
|
2015-03-04 |
2020-11-26 |
Мерк Шарп Энд Дохме Корп. |
Комбинация антагониста pd-1 и эрибулина для лечения рака
|
WO2016140717A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
MA42971A
(fr)
|
2015-03-13 |
2018-08-15 |
Cytomx Therapeutics Inc |
Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
EP3839510A3
(en)
|
2015-04-17 |
2021-08-25 |
Merck Sharp & Dohme Corp. |
Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
|
JP6681919B2
(ja)
*
|
2015-04-20 |
2020-04-15 |
イーフェクター セラピューティクス, インコーポレイテッド |
がんおよび感染症を処置する際に使用するための免疫チェックポイントモジュレーターの阻害剤
|
US20180134771A1
(en)
*
|
2015-05-07 |
2018-05-17 |
Bioxcel Corporation |
Novel immunomodulatory therapeutic strategies targeting tumors in cancer
|
CA3176224A1
(en)
*
|
2015-05-22 |
2016-12-01 |
Translational Drug Development Llc |
Benzamide and active compound compositions and methods of use
|
WO2016189055A1
(en)
|
2015-05-27 |
2016-12-01 |
Idenix Pharmaceuticals Llc |
Nucleotides for the treatment of cancer
|
CA2984638A1
(en)
*
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Pd-l1 promoter methylation in cancer
|
WO2016196173A1
(en)
|
2015-05-29 |
2016-12-08 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
|
LT3303373T
(lt)
|
2015-05-30 |
2020-07-10 |
Molecular Templates, Inc. |
Deimunizuoto shiga toksino a subvieneto karkasai ir juos apimančios ląstelės taikinio molekulės
|
CN115554399A
(zh)
*
|
2015-05-31 |
2023-01-03 |
源生公司 |
用于免疫疗法的组合组合物
|
AU2016280003B2
(en)
|
2015-06-16 |
2021-09-16 |
Merck Patent Gmbh |
PD-L1 antagonist combination treatments
|
US11369623B2
(en)
|
2015-06-16 |
2022-06-28 |
Prism Pharma Co., Ltd. |
Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
|
JP6996983B2
(ja)
*
|
2015-06-16 |
2022-02-21 |
ジェネンテック, インコーポレイテッド |
抗cll-1抗体及び使用方法
|
WO2016205320A1
(en)
*
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
GB201511790D0
(en)
|
2015-07-06 |
2015-08-19 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
EP3779998A1
(en)
*
|
2015-07-13 |
2021-02-17 |
Biodesix, Inc. |
Predictive test for melanoma patient benefit from pd-1 antibody drug and classifier development methods
|
BR112018000768A2
(pt)
|
2015-07-13 |
2018-09-25 |
Cytomx Therapeutics Inc |
anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
|
WO2017009842A2
(en)
|
2015-07-16 |
2017-01-19 |
Biokine Therapeutics Ltd. |
Compositions and methods for treating cancer
|
CN108136025B
(zh)
|
2015-07-16 |
2022-09-06 |
比奥克斯塞尔医疗股份有限公司 |
一种使用免疫调节治疗癌症的新颖方法
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
WO2017024465A1
(en)
*
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
US10106574B2
(en)
|
2015-08-13 |
2018-10-23 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as sting agonists
|
US11453697B1
(en)
|
2015-08-13 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
KR20180043835A
(ko)
|
2015-09-03 |
2018-04-30 |
에일러론 테라퓨틱스 인코포레이티드 |
펩티도미메틱 매크로사이클 및 이의 용도
|
MX2018003633A
(es)
|
2015-09-25 |
2018-08-01 |
Genentech Inc |
Anticuerpos anti-tigit y metodos de uso.
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
AU2016329120B2
(en)
|
2015-10-02 |
2023-04-13 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specific for a costimulatory TNF receptor
|
JP7320944B2
(ja)
*
|
2015-10-08 |
2023-08-04 |
マクロジェニクス,インコーポレーテッド |
B7‐h3に特異的に結合する分子及びpd‐1に特異的に結合する分子
|
EP3362475B1
(en)
|
2015-10-12 |
2023-08-30 |
Innate Pharma |
Cd73 blocking agents
|
US10875923B2
(en)
|
2015-10-30 |
2020-12-29 |
Mayo Foundation For Medical Education And Research |
Antibodies to B7-H1
|
KR20180069903A
(ko)
|
2015-11-02 |
2018-06-25 |
파이브 프라임 테라퓨틱스, 인크. |
Cd80 세포외 도메인 폴리펩타이드 및 이들의 암 치료에서의 용도
|
LT3370768T
(lt)
|
2015-11-03 |
2022-05-25 |
Janssen Biotech, Inc. |
Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas
|
ES2863225T3
(es)
|
2015-12-03 |
2021-10-11 |
Glaxosmithkline Ip Dev Ltd |
Dinucleótidos cíclicos purinos como moduladores del sting
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
WO2017106062A1
(en)
|
2015-12-15 |
2017-06-22 |
Merck Sharp & Dohme Corp. |
Novel compounds as indoleamine 2,3-dioxygenase inhibitors
|
AU2016369537B2
(en)
|
2015-12-17 |
2024-03-14 |
Novartis Ag |
Antibody molecules to PD-1 and uses thereof
|
GB201522311D0
(en)
|
2015-12-17 |
2016-02-03 |
Photocure Asa |
Use
|
GB201522309D0
(en)
|
2015-12-17 |
2016-02-03 |
Photocure Asa |
Use
|
CN115350279A
(zh)
|
2016-01-07 |
2022-11-18 |
博笛生物科技有限公司 |
用于***的抗-her2组合
|
CN106943596A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技(北京)有限公司 |
用于***的抗-cd20组合
|
CN115252792A
(zh)
|
2016-01-07 |
2022-11-01 |
博笛生物科技有限公司 |
用于***的抗-egfr组合
|
AU2017205089B2
(en)
*
|
2016-01-08 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
|
KR20180101549A
(ko)
|
2016-01-21 |
2018-09-12 |
이나뜨 파르마 |
림프구에서의 저해 경로의 중화
|
JP7089474B2
(ja)
|
2016-01-22 |
2022-06-22 |
マブクエスト エスエー |
免疫学的試薬
|
US11214617B2
(en)
|
2016-01-22 |
2022-01-04 |
MabQuest SA |
Immunological reagents
|
US11710539B2
(en)
|
2016-02-01 |
2023-07-25 |
Biodesix, Inc. |
Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy
|
CN108699158B
(zh)
|
2016-03-08 |
2022-06-03 |
依奈特制药公司 |
Siglec中和抗体
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
WO2017160754A1
(en)
|
2016-03-15 |
2017-09-21 |
Mersana Therapeutics,Inc. |
Napi2b-targeted antibody-drug conjugates and methods of use thereof
|
EP4112641A1
(en)
*
|
2016-03-15 |
2023-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
|
WO2017165742A1
(en)
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
|
JP7069032B2
(ja)
|
2016-03-24 |
2022-05-17 |
ミレニアム ファーマシューティカルズ, インコーポレイテッド |
がん免疫治療における胃腸の免疫関連有害事象の治療方法
|
US20200232974A1
(en)
|
2016-03-30 |
2020-07-23 |
Centre Léon-Bérard |
Lymphocytes expressing cd73 in cancerous patient dictates therapy
|
US10975287B2
(en)
|
2016-04-07 |
2021-04-13 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators
|
CR20200044A
(es)
|
2016-04-07 |
2020-03-11 |
Glaxosmithkline Ip Dev Ltd |
AMIDAS HETEROCÍCLICAS ÚTILES COMO MODULADORES DE PROTEÍNAS (Divisional 2018-0472)
|
KR102418766B1
(ko)
|
2016-04-12 |
2022-07-08 |
일라이 릴리 앤드 캄파니 |
암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법
|
KR20190003957A
(ko)
|
2016-04-15 |
2019-01-10 |
제넨테크, 인크. |
암 모니터링 및 치료 방법
|
EP3449015A1
(en)
*
|
2016-04-27 |
2019-03-06 |
Mira DX, Inc. |
Immune-based treatment of kras-variant cancer patients
|
WO2017192874A1
(en)
|
2016-05-04 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Albumin-binding immunomodulatory compositions and methods of use thereof
|
CA3023157A1
(en)
|
2016-05-05 |
2017-11-09 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Enhancer of zeste homolog 2 inhibitors
|
TWI822521B
(zh)
|
2016-05-13 |
2023-11-11 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
WO2017200969A1
(en)
*
|
2016-05-20 |
2017-11-23 |
Eli Lilly And Company |
Combination therapy with notch and pd-1 or pd-l1 inhibitors
|
BR112018075598A2
(pt)
|
2016-06-08 |
2019-03-26 |
Glaxosmithkline Intellectual Property Development Limited |
compostos químicos
|
KR20190015492A
(ko)
|
2016-06-08 |
2019-02-13 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
화학적 화합물
|
US10864203B2
(en)
|
2016-07-05 |
2020-12-15 |
Beigene, Ltd. |
Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
JP2019521166A
(ja)
|
2016-07-20 |
2019-07-25 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Perk阻害剤としてのイソキノリン誘導体
|
WO2018029124A1
(en)
*
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
FI3500299T3
(fi)
|
2016-08-19 |
2024-02-14 |
Beigene Switzerland Gmbh |
Tsanubrutinibin yhdistelmä cd20-tai pd-1-vasta-aineen kanssa käytettäväksi syövän hoidossa
|
CN109790220A
(zh)
|
2016-08-25 |
2019-05-21 |
豪夫迈·罗氏有限公司 |
与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
|
AU2017335839A1
(en)
*
|
2016-09-29 |
2019-04-18 |
Genentech, Inc. |
Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a taxane
|
ES2893532T3
(es)
|
2016-10-04 |
2022-02-09 |
Merck Sharp & Dohme |
Compuestos de benzo[b]tiofeno como agonistas de STING
|
BR112019006504A2
(pt)
|
2016-10-06 |
2019-06-25 |
Merck Patent Gmbh |
regime de dosagem de avelumabe para o tratamento de câncer
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
SG11201902974PA
(en)
|
2016-10-14 |
2019-05-30 |
Merck Sharp & Dohme |
Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
|
EP4295918A3
(en)
|
2016-11-02 |
2024-03-20 |
Bristol-Myers Squibb Company |
Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
|
AU2017356860A1
(en)
|
2016-11-08 |
2019-05-16 |
Qilu Puget Sound Biotherapeutics Corporation |
Anti-PD1 and anti-CTLA4 antibodies
|
US20190365788A1
(en)
|
2016-11-21 |
2019-12-05 |
Idenix Pharmaceuticals Llc |
Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
RU2765410C2
(ru)
|
2016-11-30 |
2022-01-28 |
Онкомед Фармасьютикалс, Инк. |
Способы лечения рака, включающие связывающие tigit агенты
|
JP2020511407A
(ja)
|
2016-12-01 |
2020-04-16 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
併用療法
|
US20190343803A1
(en)
|
2016-12-01 |
2019-11-14 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
WO2018111890A1
(en)
*
|
2016-12-12 |
2018-06-21 |
Genentech, Inc. |
Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
|
JP7304287B2
(ja)
|
2016-12-22 |
2023-07-06 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗pd-l1/pd1治療の不成功後の、抗pd-l1抗体との組み合わせでの抗csf-1r抗体を用いた腫瘍の治療
|
CN108239149B
(zh)
*
|
2016-12-25 |
2021-03-05 |
南京传奇生物科技有限公司 |
高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人pd-l1抗体
|
CN110383069A
(zh)
|
2017-01-05 |
2019-10-25 |
佰欧迪塞克斯公司 |
用于鉴定总体不良预后亚组中持久受益于免疫疗法的癌症患者的方法
|
EA039433B1
(ru)
|
2017-01-05 |
2022-01-27 |
Нетрис Фарма |
Комбинированное лечение лекарственными средствами, интерферирующими с нетрином-1, и лекарственными средствами, ингибиторами контрольных точек иммуного ответа
|
WO2018137681A1
(en)
|
2017-01-25 |
2018-08-02 |
Beigene, Ltd. |
Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
|
ES2891326T3
(es)
|
2017-01-27 |
2022-01-27 |
Janssen Biotech Inc |
Dinucleótidos cíclicos como agonistas de la STING
|
EP3573718B1
(en)
|
2017-01-27 |
2022-06-01 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
US20200023071A1
(en)
|
2017-02-06 |
2020-01-23 |
Innate Pharma |
Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
|
JP7324710B2
(ja)
|
2017-02-21 |
2023-08-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
肺癌の処置のための抗pd-1抗体
|
CN108503691B
(zh)
*
|
2017-02-25 |
2021-07-23 |
复旦大学 |
一种人pd-l1蛋白高亲和性肽及其应用
|
JP2020509009A
(ja)
|
2017-02-27 |
2020-03-26 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
キナーゼ阻害剤としての複素環式アミド
|
TW201834697A
(zh)
|
2017-02-28 |
2018-10-01 |
美商梅爾莎納醫療公司 |
Her2標靶抗體-藥物結合物之組合療法
|
EP3596469A1
(en)
|
2017-03-12 |
2020-01-22 |
Yeda Research and Development Co., Ltd. |
Methods of diagnosing and prognosing cancer
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
KR102584011B1
(ko)
|
2017-03-16 |
2023-09-27 |
이나뜨 파르마 에스.에이. |
암 치료를 위한 조성물 및 방법
|
EP3600410A1
(en)
|
2017-03-30 |
2020-02-05 |
Merck Patent GmbH |
Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
MX2019012849A
(es)
|
2017-04-28 |
2019-11-28 |
Five Prime Therapeutics Inc |
Metodos de tratamiento con polipeptidos del dominio extracelular del cd80.
|
US11466047B2
(en)
|
2017-05-12 |
2022-10-11 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
US11685787B2
(en)
|
2017-05-16 |
2023-06-27 |
Bristol-Myers Squibb Company |
Treatment of cancer with anti-GITR agonist antibodies
|
BR112019025188A2
(pt)
|
2017-06-01 |
2020-06-23 |
Cytomx Therapeutics, Inc. |
Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
|
WO2018225093A1
(en)
|
2017-06-07 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds as atf4 pathway inhibitors
|
KR20200015717A
(ko)
|
2017-06-09 |
2020-02-12 |
프로비던스 헬스 앤드 서비시즈 - 오레곤 |
암 치료를 위한 인간 종양 반응성 t 세포의 확인을 위한 cd39 및 cd103의 활용
|
BR112019025325A2
(pt)
|
2017-06-09 |
2020-06-23 |
Glaxosmithkline Intellectual Property Development Limited |
Métodos para tratar câncer, para fabricar um anticorpo anti-icos ou porção de ligação a antígeno do mesmo, para fabricar um anticorpo anti-pd1 ou porção de ligação a antígeno do mesmo, para fabricar um anticorpo anti-pdl1 ou porção de ligação a antígeno do mesmo, anticorpo anti-icos ou fragmento de ligação a antígeno do mesmo e um anticorpo anti-pd1 ou fragmento de ligação a antígeno do mesmo, anticorpo anti-icos ou fragmento de ligação a antígeno do mesmo e um anticorpo anti-pd-l1 ou fragmento de ligação a antígeno do mesmo, uso de um anticorpo anti-icos ou porção de ligação a antígeno do mesmo e um anticorpo anti-pd1 ou porção de ligação a antígeno do mesmo, polinucleotídeo, vetor, e, célula hospedeira
|
RU2020102453A
(ru)
|
2017-06-23 |
2021-07-23 |
Бирди Байофармасьютикалз, Инк. |
Фармацевтические композиции
|
EP3645569A4
(en)
|
2017-06-26 |
2021-03-24 |
BeiGene, Ltd. |
IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
|
EP3649108A1
(en)
|
2017-07-03 |
2020-05-13 |
GlaxoSmithKline Intellectual Property Development Limited |
2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
|
EP3649106A1
(en)
|
2017-07-03 |
2020-05-13 |
GlaxoSmithKline Intellectual Property Development Limited |
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-cyclobutane-1-carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
|
EP3652208A1
(en)
|
2017-07-10 |
2020-05-20 |
Innate Pharma |
Siglec-9-neutralizing antibodies
|
US11293066B2
(en)
|
2017-07-18 |
2022-04-05 |
Institut Gustave Roussy |
Method for assessing the response to PD-1/PDL-1 targeting drugs
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
MA49772A
(fr)
|
2017-08-04 |
2021-04-21 |
Merck Sharp & Dohme |
Agonistes benzo[b]thiophène de sting pour le traitement du cancer
|
AU2018311965A1
(en)
|
2017-08-04 |
2020-02-13 |
Merck Sharp & Dohme Llc |
Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
|
TW201922721A
(zh)
|
2017-09-07 |
2019-06-16 |
英商葛蘭素史克智慧財產發展有限公司 |
化學化合物
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
CA3077337A1
(en)
|
2017-10-05 |
2019-04-11 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (sting)
|
US20210238172A1
(en)
|
2017-10-05 |
2021-08-05 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators and methods of using the same
|
SG11202002192QA
(en)
|
2017-10-06 |
2020-04-29 |
Innate Pharma |
Restoration of t cell activity via the cd39/cd73 axis
|
CN109663130B
(zh)
*
|
2017-10-13 |
2021-06-29 |
江苏恒瑞医药股份有限公司 |
Pd-1抗体和mek抑制剂联合在制备***的药物中的用途
|
AU2018353432A1
(en)
|
2017-10-19 |
2020-04-23 |
Debiopharm International S.A. |
Combination product for the treatment of cancer
|
EP3703692A4
(en)
|
2017-11-01 |
2021-04-28 |
Merck Sharp & Dohme Corp. |
NEW SUBSTITUTED TETRAHYDROQUINOLINE COMPOUNDS USED AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS
|
WO2019099294A1
(en)
|
2017-11-14 |
2019-05-23 |
Merck Sharp & Dohme Corp. |
Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
|
WO2019099314A1
(en)
|
2017-11-14 |
2019-05-23 |
Merck Sharp & Dohme Corp. |
Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
|
WO2019099838A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Combination therapies
|
EP3717021A1
(en)
|
2017-11-27 |
2020-10-07 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
WO2019108795A1
(en)
|
2017-11-29 |
2019-06-06 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
|
CN108165536A
(zh)
*
|
2017-12-11 |
2018-06-15 |
浙江大学 |
一种重组溶瘤痘苗病毒及其制备方法与应用
|
US20210009630A1
(en)
|
2017-12-15 |
2021-01-14 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
US11685761B2
(en)
|
2017-12-20 |
2023-06-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
JP2021506883A
(ja)
|
2017-12-21 |
2021-02-22 |
メルサナ セラピューティクス インコーポレイテッド |
ピロロベンゾジアゼピン抗体結合体
|
CA3082280A1
(en)
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against tigit
|
KR20200106921A
(ko)
*
|
2018-01-10 |
2020-09-15 |
어레이 바이오파마 인크. |
암을 치료하기 위한 방법 및 조합 요법
|
CA3084518A1
(en)
|
2018-01-15 |
2019-07-18 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against pd-1
|
MA54118A
(fr)
|
2018-01-31 |
2021-09-15 |
Celgene Corp |
Polythérapie utilisant une thérapie cellulaire adoptive et un inhibiteur de point de contrôle
|
CA3093499A1
(en)
|
2018-03-14 |
2019-09-19 |
Merck Patent Gmbh |
Compounds and uses thereof to treat tumors in a subject
|
EP3774764A1
(en)
|
2018-04-03 |
2021-02-17 |
Merck Sharp&Dohme Corp. |
Benzothiophenes and related compounds as sting agonists
|
US11702430B2
(en)
|
2018-04-03 |
2023-07-18 |
Merck Sharp & Dohme Llc |
Aza-benzothiophene compounds as STING agonists
|
WO2019193540A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Heteroaryl derivatives of formula (i) as atf4 inhibitors
|
WO2019193541A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
|
EP3781687A4
(en)
|
2018-04-20 |
2022-02-09 |
Merck Sharp & Dohme Corp. |
NEW RIG-I SUBSTITUTED AGONISTS: COMPOSITIONS AND METHODS THEREOF
|
RU2020136057A
(ru)
|
2018-05-04 |
2022-05-04 |
Толлиз |
Лиганды tlr3, которые активируют как эпителиальные, так и миелоидные клетки
|
CN112512576A
(zh)
|
2018-05-04 |
2021-03-16 |
默克专利有限公司 |
PD-1/PD-L1、TGFβ和DNA-PK联合抑制用于治疗癌症
|
US20210107980A1
(en)
*
|
2018-05-07 |
2021-04-15 |
Genmab A/S |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
JOP20200303A1
(ar)
|
2018-05-24 |
2020-11-23 |
Janssen Biotech Inc |
عوامل ربط psma واستخداماتها
|
EP3810109A4
(en)
|
2018-05-31 |
2022-03-16 |
Peloton Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR INHIBITING CD73
|
US11352320B2
(en)
|
2018-05-31 |
2022-06-07 |
Merck Sharp & Dohme Corp. |
Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
|
CN112566938A
(zh)
|
2018-06-03 |
2021-03-26 |
拉姆卡普生物测试有限公司 |
针对ceacam5和cd47的双特异性抗体
|
EP3808376A4
(en)
|
2018-06-17 |
2021-09-01 |
L&L Biopharma Co., Ltd. |
CLDN18.2 ANTIBODY, BISPECIFIC ANTIBODY, ADC AND CAR, AND APPLICATIONS THEREOF
|
EP3807316B1
(en)
|
2018-06-18 |
2024-05-01 |
Innate Pharma |
Compositions and methods for treating cancer
|
CN110669135B
(zh)
|
2018-07-03 |
2022-11-11 |
上海健信生物医药科技有限公司 |
一种双特异性抗体及其用途
|
WO2020012339A1
(en)
|
2018-07-09 |
2020-01-16 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
EP3820992A2
(en)
|
2018-07-11 |
2021-05-19 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
EP3827020A1
(en)
|
2018-07-24 |
2021-06-02 |
Amgen Inc. |
Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
|
WO2020031107A1
(en)
|
2018-08-08 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
WO2020044206A1
(en)
|
2018-08-29 |
2020-03-05 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides as kinase inhibitors for use in the treatment cancer
|
SG11202102343QA
(en)
|
2018-09-11 |
2021-04-29 |
Curis Inc |
Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
|
CN113286614A
(zh)
|
2018-09-26 |
2021-08-20 |
默克专利股份有限公司 |
用于治疗癌症的pd-1拮抗剂、atr抑制剂和铂化物质的组合
|
IL282317B2
(en)
|
2018-10-17 |
2024-04-01 |
Biolinerx Ltd |
Treatment of metastatic adenocarcinoma of the pancreas
|
CA3117746A1
(en)
|
2018-10-22 |
2020-04-30 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing
|
AU2019369340A1
(en)
|
2018-10-29 |
2021-05-20 |
Mersana Therapeutics, Inc. |
Cysteine engineered antibody-drug conjugates with peptide-containing linkers
|
US20210395240A1
(en)
|
2018-11-01 |
2021-12-23 |
Merck Sharp & Dohme Corp. |
Novel substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
|
WO2020096871A1
(en)
|
2018-11-06 |
2020-05-14 |
Merck Sharp & Dohme Corp. |
Novel substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors
|
SG11202105078XA
(en)
*
|
2018-11-14 |
2021-06-29 |
Bayer Ag |
Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer
|
CN113301899A
(zh)
|
2018-11-16 |
2021-08-24 |
艾科尔公司 |
用于治疗癌症的药物组合
|
CN113015530A
(zh)
|
2018-11-20 |
2021-06-22 |
默沙东公司 |
取代的氨基***并嘧啶和氨基***并吡嗪腺苷受体拮抗剂、药物组合物及其用途
|
EP3883576A4
(en)
|
2018-11-20 |
2022-06-22 |
Merck Sharp & Dohme Corp. |
SUBSTITUTED AMINOTRIAZOLOPYRIMIDINES AND AMINO-TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
|
EP3886842A1
(en)
|
2018-11-26 |
2021-10-06 |
Debiopharm International SA |
Combination treatment of hiv infections
|
EP3886845A4
(en)
|
2018-11-28 |
2022-08-10 |
Merck Sharp & Dohme Corp. |
NEW SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS USED AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS
|
EP3886988A1
(en)
|
2018-11-30 |
2021-10-06 |
Merck Sharp & Dohme Corp. |
9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
|
IL310831A
(en)
|
2018-11-30 |
2024-04-01 |
Glaxosmithkline Ip Dev Ltd |
Compounds useful in curing HIV
|
WO2020123453A2
(en)
|
2018-12-11 |
2020-06-18 |
Theravance Biopharma R&D Ip, Llc |
Alk5 inhibitors
|
JP2022514315A
(ja)
|
2018-12-20 |
2022-02-10 |
ノバルティス アーゲー |
3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体を含む投与計画及び薬剤組み合わせ
|
WO2020128893A1
(en)
|
2018-12-21 |
2020-06-25 |
Pfizer Inc. |
Combination treatments of cancer comprising a tlr agonist
|
WO2020165833A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
JP7488826B2
(ja)
|
2019-02-15 |
2024-05-22 |
ノバルティス アーゲー |
置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
|
CN109879855B
(zh)
*
|
2019-03-26 |
2021-01-05 |
中国医学科学院医药生物技术研究所 |
靶向肿瘤细胞表面pd-l1分子的抑制剂及其应用
|
WO2020205688A1
(en)
|
2019-04-04 |
2020-10-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
KR20220002899A
(ko)
|
2019-04-19 |
2022-01-07 |
얀센 바이오테크 인코포레이티드 |
항-psma/cd3 항체로 전립선암을 치료하는 방법
|
JP2022530404A
(ja)
|
2019-04-23 |
2022-06-29 |
イナート・ファルマ・ソシエテ・アノニム |
Cd73遮断抗体
|
JP2022533194A
(ja)
|
2019-05-16 |
2022-07-21 |
スティングセラ インコーポレイテッド |
ベンゾ[b][1,8]ナフチリジン酢酸誘導体および使用方法
|
CN114302875A
(zh)
|
2019-05-16 |
2022-04-08 |
斯汀塞拉股份有限公司 |
氧代吖啶基乙酸衍生物及使用方法
|
WO2020239558A1
(en)
|
2019-05-24 |
2020-12-03 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
WO2020260547A1
(en)
|
2019-06-27 |
2020-12-30 |
Rigontec Gmbh |
Design method for optimized rig-i ligands
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
WO2021012092A1
(en)
*
|
2019-07-19 |
2021-01-28 |
Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. |
A novel anti-pd-l1 antibody and use thereof
|
US11083705B2
(en)
|
2019-07-26 |
2021-08-10 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition for treating tumor
|
AU2020324388A1
(en)
|
2019-08-02 |
2022-02-24 |
Mersana Therapeutics, Inc. |
Bis-[N-((5-carbamoyl)-1H-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as STING (Stimulator of Interferon Genes) agonists for the treatment of cancer
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
KR20220113353A
(ko)
|
2019-09-18 |
2022-08-12 |
람캅 바이오 알파 에이지 |
Ceacam5 및 cd3에 대한 이중특이적 항체
|
EP4031573A1
(en)
|
2019-09-20 |
2022-07-27 |
Transgene |
Combination of a poxvirus encoding hpv polypeptides and il-2 with an anti-pd-l1 antibody
|
TW202128755A
(zh)
|
2019-09-27 |
2021-08-01 |
英商葛蘭素史密斯克藍智慧財產發展有限公司 |
抗原結合蛋白
|
CN112724127B
(zh)
|
2019-10-28 |
2023-02-17 |
中国科学院上海药物研究所 |
五元杂环氧代羧酸类化合物及其医药用途
|
EP4051278A1
(en)
|
2019-10-29 |
2022-09-07 |
Eisai R&D Management Co., Ltd. |
Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer
|
MX2022006213A
(es)
|
2019-11-22 |
2022-06-22 |
Theravance Biopharma R&D Ip Llc |
Piridinas sustituidas y metodos de uso.
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
WO2021113679A1
(en)
|
2019-12-06 |
2021-06-10 |
Mersana Therapeutics, Inc. |
Dimeric compounds as sting agonists
|
US20230056470A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
JP2023519673A
(ja)
|
2020-03-31 |
2023-05-12 |
セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー |
置換ピリミジンおよび使用方法
|
CA3175490A1
(en)
|
2020-04-14 |
2021-10-21 |
Glaxosmithkline Intellectual Property Limited |
Combination treatment for cancer based upon an icos antibody and a pd-l1 antibody tgf-beta-receptor fusion protein
|
TW202206100A
(zh)
|
2020-04-27 |
2022-02-16 |
美商西健公司 |
癌症之治療
|
MX2022013843A
(es)
|
2020-05-06 |
2022-11-30 |
Merck Sharp & Dohme Llc |
Inhibidores de il4i1 y metodos de uso.
|
WO2021249969A1
(en)
|
2020-06-10 |
2021-12-16 |
Merck Patent Gmbh |
Combination product for the treatment of cancer diseases
|
WO2021253041A1
(en)
|
2020-06-10 |
2021-12-16 |
Theravance Biopharma R&D Ip, Llc |
Naphthyridine derivatives useful as alk5 inhibitors
|
TWI811703B
(zh)
|
2020-06-19 |
2023-08-11 |
瑞士商赫孚孟拉羅股份公司 |
與cd3及cd19結合之抗體
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
WO2021260675A1
(en)
|
2020-06-24 |
2021-12-30 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
US20230250173A1
(en)
|
2020-07-01 |
2023-08-10 |
Pfizer Inc. |
Biomarkers for pd-1 axis binding antagonist therapy
|
MX2023000197A
(es)
|
2020-07-07 |
2023-02-22 |
BioNTech SE |
Arn terapeutico para el cancer positivo para vph.
|
CA3189987A1
(en)
|
2020-09-02 |
2022-03-10 |
Pharmabcine Inc. |
Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer
|
AU2021400227A1
(en)
|
2020-12-18 |
2023-04-27 |
Lamkap Bio Beta Ltd |
Bispecific antibodies against ceacam5 and cd47
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性rna
|
KR20230137393A
(ko)
|
2021-01-28 |
2023-10-04 |
얀센 바이오테크 인코포레이티드 |
Psma 결합 단백질 및 이의 용도
|
CA3206906A1
(en)
|
2021-02-02 |
2022-08-11 |
Andras Herner |
Selective bcl-xl protac compounds and methods of use
|
CA3212345A1
(en)
|
2021-03-02 |
2022-09-09 |
Glaxosmithkline Intellectual Property Development Limited |
Substituted pyridines as dnmt1 inhibitors
|
JP2024511373A
(ja)
|
2021-03-18 |
2024-03-13 |
ノバルティス アーゲー |
がんのためのバイオマーカーおよびその使用
|
TW202304506A
(zh)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
涉及抗claudin 18.2抗體的組合治療以治療癌症
|
US20240166747A1
(en)
|
2021-03-31 |
2024-05-23 |
Glazosmithkline Intellectual Property Development Limited |
Antigen binding proteins and combinations thereof
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
KR20230167407A
(ko)
|
2021-04-08 |
2023-12-08 |
누릭스 테라퓨틱스 인코포레이티드 |
Cbl-b 억제제 화합물을 이용한 조합 요법
|
WO2022214652A1
(en)
|
2021-04-09 |
2022-10-13 |
Ose Immunotherapeutics |
Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
|
KR20240005741A
(ko)
|
2021-04-09 |
2024-01-12 |
오제 이뮈노테라프틱스 |
특성이 향상된 이작용성 분자용 신규한 스캐폴드
|
WO2022227015A1
(en)
|
2021-04-30 |
2022-11-03 |
Merck Sharp & Dohme Corp. |
Il4i1 inhibitors and methods of use
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
AU2022288058A1
(en)
|
2021-06-07 |
2023-11-16 |
Agonox, Inc. |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
CA3225254A1
(en)
|
2021-07-13 |
2023-01-19 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
CA3227386A1
(en)
*
|
2021-07-28 |
2023-02-02 |
Jianing Huang |
Interleukin-2 muteins, fusion proteins, pharmaceutical compositions, and therapeutic applications
|
WO2023010080A1
(en)
|
2021-07-30 |
2023-02-02 |
Seagen Inc. |
Treatment for cancer
|
WO2023039583A1
(en)
*
|
2021-09-10 |
2023-03-16 |
Trustees Of Tufts College |
Anti-pd-1 immunoglobulin polypeptides and uses thereof
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
WO2023079428A1
(en)
|
2021-11-03 |
2023-05-11 |
Pfizer Inc. |
Combination therapies using tlr7/8 agonist
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
WO2023166420A1
(en)
|
2022-03-03 |
2023-09-07 |
Pfizer Inc. |
Multispecific antibodies and uses thereof
|
WO2023172643A1
(en)
*
|
2022-03-08 |
2023-09-14 |
Whitehead Institute For Biomedical Research |
The combination of macrophage-directed immunotherapy and targeted agents for treatment of cancer
|
TW202404645A
(zh)
|
2022-05-20 |
2024-02-01 |
瑞士商諾華公司 |
Met bcl-xl抑制劑抗體-藥物結合物及其使用方法
|
WO2023225320A1
(en)
|
2022-05-20 |
2023-11-23 |
Novartis Ag |
Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
WO2023230541A1
(en)
|
2022-05-27 |
2023-11-30 |
Viiv Healthcare Company |
Piperazine derivatives useful in hiv therapy
|
WO2023242351A1
(en)
|
2022-06-16 |
2023-12-21 |
Lamkap Bio Beta Ag |
Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3
|